Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
59 hedge funds and large institutions have $27.5M invested in Syros Pharmaceuticals, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 9 closing their positions.
69,900% more call options, than puts
Call options by funds: $700K | Put options by funds: $1K
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
4% more funds holding
Funds holding: 57 → 59 (+2)
27% less capital invested
Capital invested by funds: $37.8M → $27.5M (-$10.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
CHI Advisors
New York
|
+$2.98M |
| 2 |
Goldman Sachs
New York
|
+$360K |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$339K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$192K |
| 5 |
LPL Financial
San Diego,
California
|
+$164K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ABG
Ally Bridge Group
New York
|
-$2.4M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.53M |
| 3 |
ACM
Altium Capital Management
New York
|
-$1.13M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$91.5K |
| 5 |
BlackRock
New York
|
-$75.8K |
SYRS Hedge Fund Activity: Q1 2023 in Review
59 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q1 2023, worth a combined $27.5M — down 27% from $37.8M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new SYRS positions and 9 closed out — a net gain of 3 holders — while 14 added to existing stakes and 11 trimmed.
The largest buyer was CHI Advisors, opening a new position worth an estimated $2.98M. The largest seller was Ally Bridge Group, cutting an estimated $2.4M.
- 59 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q1 2023, up from 57 in Q4 2022.
- Funds reported $27.5M of Syros Pharmaceuticals, Inc. Common Stock stock for Q1 2023, down 27% quarter-over-quarter.
- 12 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q1 2023 and 9 closed out, a net change of +3 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q1 2023 was CHI Advisors, an estimated $2.98M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q1 2023 was Ally Bridge Group, an estimated $2.4M sold.
Based on aggregated 13F filings for Q1 2023.